Indolent B-Cell Non-Hodgkin Lymphoma — Trials

Indolent B-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

617 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 172
Recruiting: 85
Ph III recruiting: 4
Growth YoY: +34.6%
Industry share: 22%
Top sponsor: City of Hope Medical Center
Termination share: 34.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (109)

clinicaltrialsPublishedShowing 101–150 of 333 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04883437	Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	recruiting	Phase 2	49	Emory UniversityOTHER	1	Feb 9, 2026	clinicaltrials
NCT04669171	A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma(SIDNEY)	recruiting	Phase 1 / Phase 2	80	EnteromeINDUSTRY	4	Jan 30, 2026